@LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent
Commentary stating that the substance reduces follicle-stimulating hormone (FSH) and luteinizing hormone (LH) modestly, with effects that depend on dose. The post does not reference any company, product, or investable security.
Linked assets
Ticker listed: LH — included as a biological marker (luteinizing hormone) referenced in the commentary. No corporate or market tickers, ETFs, or tradable instruments are identified.
@LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent @LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent
Source proof
Source proof: Supported source proof | 1 extracted claim | 1 directional asset | 1 supporting author | headline-like title review
Primary source is a social-media style comment: “@LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent.” Related posts discuss topical testosterone/DHT effects on the HPG axis and other informal health/product remarks. None of the sources link to companies, drugs, catalysts, pricing, or investment implications.
Anecdotal claim: a client reports improved nocturia/sleep continuity after taking 20mg vitamin K2 (MK-4) before bed for 4 days. No clinical data, no identifiable public-company catalyst, and unclear market relevance.
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
A social-media joke/comment about progesterone and relationship behavior; no financial, economic, or market-relevant information.
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Commentary about an unspecified substance reducing FSH and LH modestly, in a dose-dependent manner. No company, drug, catalyst, or tradable asset is identified.
Discussion about physiological effects of topical testosterone and DHT on HPG axis activity; no explicit market, company, product, or investable asset referenced.
The source only states that the user has heard “tons of strong reviews” about @JK99928789839, with no identifiable company/ticker, product, catalyst, timeframe, or tradable implication.
Non-financial social post about skincare/sun exposure increasing skin sensitivity; no market, company, or asset implications.
Supporting authors
Single author/commenter referenced by handle: @LiamCristiano. Other related posts cited include handles @dangermanisreal, @JK99928789839, @Jenibee1732, @dr4cdac, @DdrHdee79355, @daddynigga22, and @NorKris20, but those are informal comments and not company spokespeople or published research authors.
Unlock full thesis monitoring
This note is informational about physiological effects only and is not investment advice. No tradable recommendation is implied beyond the stated biological observation.